REVIEWS ON CGD
Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther. 2007 Jun; 7(3):155-61. Review. Ott MG, Seger R, Stein S, Siler U, Hoelzer D, Grez M.
Progress and prospects: gene therapy clinical trials/CGD (part 1). Gene Ther. 2007 Oct;14(20):1439-47. Review. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, YIa-Herttuala S.
Gene therapy for chronic granulomatous disease. Curr Opin Mol Ther. 2006 Oct;8(5):415-22. Review. Stein S, Siler U, Ott MG, Seger R, Grez M.
Chronic Granulomatous Disease; fundamental stages in our understanding of CGD. Med Immunol. 5: 4; 2006.
Tracy Assari. This article is available from http://www.medimmunol.com/content/5/1/4
CGD REGISTRIES
Chronic granulomatous disease: the European experience. PLoS ONE. 2009;4(4):e5234. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, Espanol T, Fischer A, Kurenko-Deptuch M, Mouy R, Petropoulou T, Roesler J, Seger R, Stasia MJ, Valerius NH, Weening RS, Wolach B, Roos D, Kuijpers TW.
Article available at
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0005234
Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008 May: 152(2):211-8. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A., Goldblatt D, Parker L, Cant AJ.
Article available at
http://www3.interscience.wiley.com/journal/119389133/abstract?CRETRY=1&SRETRY=0
GENE AND CELLULAR THERAPY
Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Zou J, Sweeney CL, Chou BK, Pan J, Wang H, Dowey SN, Cheng L, Malech HL. Blood. 2011 May 26;117(21):5561-72.
Generation of Functional Neutrophils from a Mouse Model of X-Linked Chronic Granulomatous Disorder Using Induced Pluripotent Stem Cells. Mukherjee S, Santilli G, Blundell MP, Navarro S, Bueren JA, Thrasher AJ. PLoS One. 2011 Mar 3;6(3):e17565.
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017565
Gene therapy of chronic granulomatous disorder: the engraftment dilemma. Mol Ther. 2011 Jan;19(1):28-35. Grez M, Reichenbach J, Schwäble J, Seger R, Dinauer MC, Thrasher AJ.
Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol. Ther 2011 Jan;19(1):122-32. Epub 2010 Oct 26. Santilli G, Almarza E, Brendel C, Choi U, Bejlin C, Blundell MP, Haria S, Parsley KL, Kinnon C, Malech HL, Bueren JA, Grez M, Thrasher AJ.
Correction of SCID-X1 using an enhancerless vav promoter. Hum. Gene Ther 2010 Oct 1. [Epub ahead of print]. Almarza E, Zhang F, Santilli G, Blundell M, Howe SJ, Thornhill SI, Bueren J, Thrasher A.
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010, 16:198-204. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M.
A new PG13-based packaging cell line for stable production of clinical grade self inactivating -retroviral vectors using targeted integration. Gene Therapy 2010, 17:272-280. Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H, Stein S, Thornhill S, Thrasher AJ, Baum C , Schambach A.
Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Therapy 2009, 16:1452-1464.Sadat MA, Dirscherl S, Sastry L, Dantzer J, Pech N, Griffin S, Hawkins T, Zhao Y, Barese CN, Cross S, Orazi A, An C, Goebel WS, Yoder MC, Li X, Grez M, Cornetta K, Mooney SD, Dinauer MC.
Transgene optimization significantly improves SIN vector titers, gp91(phox) expression and reconstitution of superoxide production in X-CGD cells. Gene Therapy 2009, 16:111-118.Moreno-Carranza B., Gentsch M., Stein S., Schambach A., Santilli G., Rudolf E., Ryser M.F., Haria S., Thrasher AJ., Baum C., Brenner S., Grez M.
Gene therapy of inherited immunodeficiencies. Expert Opin Biol Ther. 2008 apr:8(4):397-407. Santilli G, Thornhill SI, Kinnon C, Thrasher AJ
Gene therapy for primary immunodeficiencies. Immunol.Allergy Clin. North America. 2008, 28 (2): 457-471. Thrasher AJ
Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther. 2009 Jan;16(1):111-8.Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudof E, Ryser MF, Haria S, Thrasher Aj, Baum C, Brenner S, Grez M.
Lentiviral vectors containing an enhancer-less ubiquitously-acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in haematopoietic cells. Blood.2007 Sep 1;110(5):1448-57.Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Scahmbach A, Sinclair J, Kinnon C, Gaspar HB, Antoniou M, Thrasher AJ.
Article available at
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2629730&tool+pmcentrez
Liposome-mediated cellular delivery of active gp91. PLoS ONE. 2007 Sep;12:2(9):e856. Marques B, Liguori L, Paclet MH, Villegas-Mendez A, Rothe R, Morel F, Lenormand JL. Article available at
www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000856
Correction of X-linked Chronic Granulomatous Disease by gene therapy, augmented by insertional activation of MDS/EVI1, PRDM16 or SETBP1. Nature Medicine 12:401-409, 2006.
MG Ott, M Schmidt, K Schwarzwaelder, S Stein, U Siler, U Koehl, H Glimm, K Kühlcke, A Schilz, H Kunkel, S Naundorf, A Brinkmann, A Deichmann, M Fischer, C Ball, I Pilz, C Dunbar, Y Du, NA Jenkins, NG Copeland, U Lüthi, M Hassan, AJ Thrasher, D Hoelzer, C von Kalle, R Seger, M Grez.
Successful reconstitution of immune function in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 14(4):505-13, 2006.
HB Gaspar, E Bjorkegren, K Parsley, K Gilmour, D King, J Sinclair, S Adams, LD Fairbanks, J Gaspar, L Henderson, EG Davies, KC Veys, AJ Thrasher.
Failure of SCID-X1 gene therapy in older patients. Blood, 105:4255-4257, 2005.
AJ Thrasher, S Hacein-Bey-Abina, HB Gaspar, S Blanche, EG Davies, K Parsley, K Gilmour, D King, S Howe, J Sinclair, C Hue, F Carlier, C von Kalle, BG de Saint, F Le Deist, A Fischer, M Cavazzana-Calvo.
Gene therapy for lympho-hematopoietic disorders. Current Hematology Reports 4:305-309, 2005.
AJ Thrasher, and HB Gaspar.
Gene therapy in primary immunodeficiency. Expert Opin Biol Ther. 5:1175-82, 2005.
AJ Thrasher and HB Gaspar.
Successful gene therapy of SCID-X1 using a pseudotyped gammaretroviral vector. Lancet, 364(9452):2181-7, 2004.
Gaspar HB, Parsley K, Howe S, King D, Gilmour KC, Sinclair J, White H, Smith J, Barington T, Jacobsen M, Christensen HO, Brouns G, AlGhonaim A, Schmidt M, Von Kalle c, Ali, RR, Kinnon C, Thrasher AJ.
Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD. J Gene Med, 6:6, 603-615, 2004.
Schwickerath O, Brouns, G,Thrasher, A, Kinnon C, Roes, J, Casimir, C.
Enhancer-Deleted Retroviral Vectors Can Restore High Levels of Superoxide Generation in a Mouse Model of CGD. J Gene Med. 6(6):603-15, 2004.
Schwickerath O, Brouns G, Thrasher, AJ, Kinnon C, Roes J, Casimir CM.
Differentiation-Dependent Up-Regulation of p47phox Gene Transcription is Associated with Changes in PU.1 Phosphorylation and Increased Binding Affinity. Biochem. Biophys. Res.Commun. 305, 193-202, 2003.
Marden CA, Cunninghame Graham, DS, Casimir CM.
A Functional ISRE is Required for Myeloid Transcription of the p47phox gene. Biochim. et Biophys. Acta 1630 117-122. 2003.
Marden, CM, Cunninghame Graham D, Thrasher AJ, Casimir, C.M.
High-level transduction and gene expression in haematopoietic repopulating cells using a human immunodeficiency virus type-1 based lentiviral vector containing an internal spleen focus forming virus promoter. Human Gene Therapy 13:803-813, 2003.
Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M,Thrasher AJ.
Mobilisation and transduction of CD34+ peripheral blood stem cells in patients with X-linked chronic granulomatous disease. J Hematotherapy & Stem Cell Research: 11: 683-694, 2002.
Ott MG, H Merget-Millitzer, OG Ottmann, H Martin, N Brüggenolte, H Bialek, R Seger, JP Hossle, D.Hoelzer, M Grez.
Gene Therapy of Hematopoietic Stem Cells: Strategies for Improvement. News Physiol Sci 17: 87-92, 2002.
Hossle JP, Seger RA, Steinhoff D.
A defined window for efficient gene marking of severe combined immunodeficient repopulating cells using a gibbon ape leukaemia virus-pseudotyped retroviral vector. Human Gene Therapy 11:91-100, 2000.
Demaison C, Brouns G, Blundell MP, Goldman JP, Levinsky RJ, Grez M, Kinnon C, Thrasher AJ.
Quality of repopulation in NOD/SCID mice engrafted with expanded cord blood CD34+ cells. Blood 94: 3269-3270, 1999.
Blundell M, Lazzari L, Demaison C, Brouns G, Goldman J, Gaspar HB, Kinnon C, Sirchia G, and Thrasher AJ.
Functional Analysis of the p47phox gene promoter. PhD Thesis, University of London (1999).
Marden CM.
ORAL PRESENTATIONS AT INTERNATIONAL CONFERENCES
Israeli Society of Gene and Cell Therapy: Lentiviruses Gene Therapy Workshop, Hadassah Hospital, Jerusalem (Co-organiser) 31 Jan-3 Feb 2010
A. Thrasher. Development of lentiviral vectors for immunodeficiencies.
American Association of Allergy, Asthma and Immunology, New Orleans, 27 Feb-2 March 2010. A. Thrasher. Update on Gene Therapies for the Treatment of PIDs.
Human Haemopoietic Stem Cell and Gene Transfer CGD Workshop, Seoul, Korea, February 2009 A. Thrasher UK Experiences of Gene Therapy for CGD
CONSERT meeting, Leukerbad, January 2009 Almarza E., Santilli G., Blundell M., Kinnon C., Grez M., Bueren J.A., Thrasher J. Optimization of gene therapy for X-CGD by the use of lentiviral vectors.
International Symposium on Immunotherapy and Immunodeficiency. German Cancer Research Center Heidelberg, 19-20 November 2009. M. Grez. Gene therapy of chronic granulomatous disease: lessons, chances and challenges.
5th Stem Cell Clonality & Genotoxicity Retreat, Hannover, 20-21 November 2009. M. Grez. Vector silencing,insertional activation of EVI1 and the induction of genomic instability in a gene therapy trial for Chronic Granulomatous Disease
European Society of Gene and Cell Therapy, Hannover, 22-25 November 2009. M. Grez. Development of lentiviral vectors for the gene therapy of X-CGD.
Hospital Infantil Vall d´Hebron , Barcelona, 8-9. December 2009. M. Grez. Gene Therapy of Chronic Granulomatous Disease: Lessons, Chances and Challenges.
Transatlantic Gene Therapy Retreat, San Diego, May 2009. A. Thrasher.
Vector Developments for PID.
International Union of Immunological Societies, Dublin, June 2009. A. Thrasher.
Gene Therapy.
Vector Development and Gene Therapy Course, German Society for Gene Therapy, Cologne, September 2009. A. Thrasher. Gene Therapy of Immune Deficiencies.
SETGyC (Spanish Gene Therapy Association), Granada, Sept - Oct 2009.
Educational Session. A. Thrasher. Gene Therapy for Immunodeficiencies.
Plenary Lecture: Regenerative medicine for primary immunodeficiencies.
5th Stem cell clonality and genotoxicity retreat, ESGCT Hannover November 2009. A. Thrasher. Gene therapy of severe combined immunodeficiency.
POSTER PRESENTATIONS AT CONFERENCES
British Society of Gene Therapy Annual Meeting, Royal Holloway, University of London, 29th-31st March 2010.
Poster presentation: Targeted lentiviral gene therapy to rescue the X-CGD phenotype. Giorgia Santilli, Christian Brendel, Elena Almarza, Chiara Beilin, Mike Blundell, Sneha Hari, Kate Parsley, Christine Kinnon, Juan A Bueren, Manuel Grez and Adrian J Thrasher.
European Society of Gene and Cell Therapy, Hannover, 22-25 November 2009. M. Grez.
Poster presentations: Vector silencing in a gene therapy trial for X-CGD and strategies to improve long term transgene expression; Gene therapy for chronic Granulomatous Disease; Ups and Downs; In vivo efficacy testing of a SIN gamma retroviral vector for the gene therapy of X-CGD; Genotoxicity analysis of a new SIN gamma retroviral vector for the gene therapy of X-CGD; Development of safety improved lentiviral vectors containing ubiquitous chromatin opening elements.
13th Annual Meeting of the American Society of Gene and Cell Therapy
San Diego, CA 27-30 May 2009.
Poster presentation: SIN gammaretroviral vectors for the gene therapy of X-CGD.
INFLAMMATION IN CGD
Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-γ in a nitric oxide-dependent manner. J.Immunol. 2010 Oct 1;185(7):4030-41. Fernandez-Boyanapalli R, McPhillips KA, Frasch SC, Janssen WJ, Dinauer MC, Riches DW, Henson PM, Byrne A, Bratton DL.
Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. J.Biol.Chem. 2011 Apr 8;286(14):12108-22. Frasch SC, Fernandez-Boyanapalli RF, Berry KZ, Leslie CC, Bonventre JV, Murphy RC, Henson PM, Bratton DL.
PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 2010 Nov 25;116(22):4512-22. Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL.
NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One. 2010 Mar 16;5(3):e9631. Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, Dennis CG, Vethanayagam RR, Yull FE, Capitano M, Wallace PK, Minderman H, Christman JW, Sporn MB, Chan J, Vinh DC, Holland SM, Romani LR, Gaffen SL, Freeman ML, Blackwell TS.
This article is available from www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0009631
The Neutrophil Respiratory Burst and Bacterial Digestion in Crohn's Disease. Dig. Dis, Sci 2010 Oct 9. [Epub ahead of print]. Hayee B, Rahman FZ, Tempero J, McCartney S, Bloom SL, Segal AW, Smith AM.
Impaired macrophage function following bacterial stimulation in chronic granulomatous disease. Immunology 2009 Oct;128(2):253-9. Rahman FZ, Hayee B, Chee R, Segal AW, Smith AM.
Intact indoleamine 2,3-dioxygenaseactivity in human chronic granulomatous disease. Clin. Immunol. 2010 Oct137 (1-3):1-4. Jurgens B, Fuchs D, Reichenbach J, Heitger, A.
Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol. 2009 Oct 1;183(7):4609-18. D'Angelo C, De Luca A, Zelante T, Bonifazi P, Moretti S, Giovannini G, Iannitti RG, Zagarella S, Bozza S, Campo S, Salvatori G, Romani L.
The prevalence of undiagnosed disorders of neutrophil function mimicking Crohn's disease. Digestive Disease Week Meeting, San Diego, USA, May 2008 A. Smith and F. Rahman .' Published in Gastroenterology 2008; 134 (Suppl 1): A14
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008 Jan 10; 451(7175):211-5. Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti MC, Groham U, Segal BH, Puccetti P.
NADPH oxidase is not required for spontaneous and Staphylococcus aureus-induced apoptosis of monocytes. Annals of Hematology 83(4):206-11, 2004. Von Bernuth H, Kulka C, Roesler J, Gahr M, Rosen-Wolff A.
Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in CGD. Journal of Leukocyte Biology: 73, 591-599, 2003. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ.
Association between p47phox pseudogenes and inflammatory bowel disease. Blood 101(8), 3337, 2003. M. Harbord, A. Hankin, S. Bloom, H. Mitchison.
Ym1 is a neutrophil granule protein that crystallizes in p47phox-deficient mice. J Biol Chem. 277(7), 5468-75, 2002. Harbord M, Novelli M, Canas B, Power D, Davis C, Godovac-Zimmermann J, Roes J, Segal AW.
Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods. 257(1-2), 213-20, 2001. Day RM, Harbord M, Forbes A, Segal AW.
POSTER PRESENTATIONS
British Society of Gastroenterology Meeting, Birmingham, March 2008 A. Smith and F. Rahman 'The prevalence of undiagnosed disorders of neutrophil function mimicking Crohn's disease.'
European Crohn's and Colitis Organisation Meeting, Lyon, France, February 2008 A. Smith and F. Rahman 'The prevalence of undiagnosed disorders of neutrophil function mimicking Crohn's disease'.
CARRIER ISSUES IN CGD
'Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology'. Clin Exp Immunol. 2007 Apr; 148(1):79-84 Cale CM, Morton L, Goldblatt D.
FIGHTING FUNGAL AND BACTERIAL INFECTIONS
Adaptive Immune Defects Against Glycoantigens in Chronic Granulomatous Disease via Dysregulated Nitric Oxide Production.
Lewis CJ, Cobb BA. Eur J Immunol. 2011 Jun 1. doi: 10.1002/eji.201141396. [Epub ahead of print]
Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. Bianchi M, Niemiec MJ, Siler U, Urban CF, Reichenbach J. J Allergy Clin Immunol. 2011 May;127(5):1243-52.e7.
Carbohydrate oxidation acidifies endosomes, regulating antigen presentation and TLR9 signaling. J Immunol. 2010 Apr 1;184(7):3789-800. Lewis CJ, Cobb, B.A. 2010.
Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis. 2009 Dec 1;49(11):1703-10. Reichenbach J, Lopatin U, Mahlaoui N, Beovic B, Siler U, Zbinden R, Seger RA, Galmiche L, Brousse N, Kayal S, Güngör T, Blanche S, Holland SM.
Restoration of NET formation by gene therapy in CGD controls aspergillosis.
Blood. 2009 Sep 24;114(13):2619-22. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, Reichenbach J.
Impaired interferon-gamma responses, increased interleukin-17 expression, and a tumor necrosis factor-alpha transcriptional program in invasive aspergillosis. J Infect Dis. 2009 Oct 15;200(8):1341-51. Armstrong-James DP, Turnbull SA, Teo I, Stark J, Rogers NJ, Rogers TR, Bignell E, Haynes K.
Virulence comparisons of Aspergillus nidulans mutants are confounded by the inflammatory response of p47phox-/- mice. Infection and Immunity 73(8): 5204-7, 2005.
Bignell E, Negrete-Urtasun S, Calcagno AM, Arst HN, Rogers T, Haynes K.
The Aspergillus pH-responsive transcription factor PacC regulates virulence. Mol Microbiol. 55(4):1072-84, 2005.
Bignell E, Negrete-Urtasun S, Calcagno AM, Haynes K, Arst HN Jr, Rogers T.
ORAL PRESENTATIONS
- 3rd Advance against Aspergillosis, Florida, USA, January 2008 B Segal 'Invasive Aspergillosis in Chronic Granulomatous Disease'.
- Blood and Fungi Meeting, November 2005.
E Bignell. Virulence comparisons of Aspergillus nidulans mutants are confounded by the inflammatory response of p47phox-/- mice.
POSTER PRESENTATIONS
- American Society for Microbiology 108th General Meeting. 'Deletion of the Aspergillus fumigatus cAMP-dependent protein kinase A regulatory subunit, pkaR, decreases virulence in a murine model of Chronic Granulomatous Disorder'. Fortwendel, J.R., Gibbons, R.S., Allen, H.L., Deepe, Jr., G.S., Newman, S.L. Askew, D.S., and Rhodes, J.C.
- 2nd Advances against Aspergillosis, Athens, Greece, February 2006.
Suzy Turnbull. Transcript profiling of the murine immune response to Aspergillus Fumigatus.
UNDERSTANDING THE ENZYME AFFECTED IN CGD
Hematologically important mutations: The autosomal recessive forms of CGD (second update). Blood Cells, Molecules and Diseases, 2010 Volume 44, 291-299.
Dirk Roos, Douglas B Kuhns, Anna Maddalana, Jacinta Bustamante, Caroline Kannengeisser, Martin de Boer, Karin van Leeuwen, M.Yavuz Koker, Baruch Wolach, Joachim Roesler, Harry L. Malech, Steven M. Holland, John I. Gallin, Marie-Jose Stasia.
Identification of a conserved Rac-binding site on NAPDPH oxidases supports a direct GTPase regulatory mechanism. J Biol Chem. 2008 May 9;283 (19): 12736-46. Kao YY, Giannis D, Bohl B, Taylor RM, Bokoch GM.
New insights into the membrane topology of the phagocyte NADPH oxidase: characterisation of an anti-gp91-phopx conformational monoclonal antibody. Campion Y., Paclet M.H., Jesaitis A.J., Marques B., Grichine A., Berthier S., Lenormand J.L., Lardy B., Stasia M.J. and Morel F. Biochimie (2007), 89, 1145-1158.
Bases moleculaires de la granulomatouse septique 'le complexe de la NADPH oxydase. Bulletin de l'Academie Nationale de Medecine (2007), 191, 377-392. Morel F.
Regulation of NADPH oxidase activity: identification of two cytochrome b558 activation states. FASEB J. (2007), 21, 1244-1255. Paclet M.H., Berthier S., Kuhn L., Garin J., and Morel F.
Single-cell optical imaging of the phagocyte NADPH oxidase. Antioxidants and Redox Signaling, Antioxid Redox Signal. 1509-22, 2006.
H-J van Manen, R van Bruggen, D Roos, C Otto.
Raman microscopy of phagocytosis: shedding light on macrophage foam cell formation. Proc. SPIE Vol. 6093, 60930I-1, 2006.
H-J van Manen, AA van Apeldoorn, D Roos, C Otto.
Single-cell Raman and fluorescence microscopy reveal the association of lipid bodies with phagosomes in leukocytes. Proc Natl Acad Sci USA 102(29):10159-64, 2005.
Van Manen HJ, Kraan YM, Roos D, Otto C.
Continuous translocation of Rac2 and the NADPH oxidase component p67(phox) during phagocytosis. J Biol Chem. 279(10):9097-102, 2004.
Van Bruggen R, Anthony E, Fernandez-Borja M, Roos D.
Intracellular chemical imaging of heme-containing enzymes involved in innate immunity using resonance Raman microscopy. J.Phys. Chem B 108, 18762-18771, 2004.
van Manen HJ, Kraan YM, Roos D, Otto C.
Resonance Raman imaging of the NADPH oxidase subunit cytochrome b558 in single neutrophilic granulocytes. J.Am. Chem. Soc. 125: 12112-12113, 2003.
Van Manen H-J, Uzunbajakava Nvan Bruggen R, Roos D, Otto C.
Non-reasonant confocal Raman imaging of DNA and protein distribution in apoptotic cells. Biophy. J. 84: 3968-3981, 2003.
Uzunbajakava N, Lenferink A, Kraan Y, Volokhina E, Vrensen G, Greve J, Otto C.
ORAL PRESENTATIONS
- The Institute for Advanced Studies, The Hebrew University of Jerusalem, Jerusalem, Israel, October 6-11, 2007. Gary M. Bokoch 'Signal Transduction in Host-Bacterial Interactions'
- Gordon Research Conference on Phagocytes, Rhode Island, USA., June, 2007 G. Bokoch 'Regulation of NADPH oxidases by Rac GTpases'.
- Focus on Microscopy 2004. Philadelphia. USA, 2004
D Roos and C Otto. Confocal Raman imaging of cytochrome b558 in single cells. - European Conference of the Spectroscopy of Biomolecules (ECSBM) Aschaffenburg Germany, September 2005.
C Otto. Single cell Raman and fluorescence microscopy of leukocytes. - Spec2006: Shedding light on Disease; Optical Diagnosis for the New Millenium, Heidelberg, Germany, May 2006.
C Otto. Lipid Droplets: a new player in the molecular mechanism of the immune response in neutrophilic granulocytes. - Photonics West – Biomedical Optics, January 2006, San Jose, CA, USA.
H-J van Manen, D Roos, V Subramaniam, C Otto. Raman microscopy of phagocytosis: shedding light on innate immunity. - Annual Dutch Meeting on Cellular and Molecular Biophysics, October 2006, Lunteren, The Netherlands.
H-J van Manen, D Roos, V Subramaniam, C Otto. Raman imaging reveals a role for lipid droplets in the innate immune response.
IMPORTANT NOTE :
The information contained on this website is intended only as a guideline, not as a substitute for medical advice. Always consult your doctor if you or your child has any CGD symptoms or concerns.
© 2001-2007 The Chronic Granulomatous Disorder (CGD) Research Trust
Registered Charity No. 1003425 email:cgd@cgdrt.co.uk
The CGD Research Trust is a member of the Association of Medical Research Charities (AMRC), the Genetic Interest Group (GiG) and an associate member of the International Patient Organisation of Primary Immunodeficiencies (IPOPI)
Site Map | Terms and Conditions | Privacy
